LMND:NYSELemonade, Inc. Analysis
Data as of 2026-05-25 - not real-time
$56.52
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Lemonade’s stock is trading at $56.52, well below its 20‑day ($56.14), 50‑day ($60.29) and 200‑day ($63.89) simple moving averages, signaling a bearish technical backdrop. The price sits just above the identified support at $50.80 and faces resistance near $68.05, while the RSI of 48 indicates neutral momentum and a bullish MACD histogram (+0.40) hints at a possible short‑term reversal. However, volume is on a decreasing trend and 30‑day volatility is extremely high at 74.7%, compounded by a beta of 2.79, underscoring significant price swings.
Fundamentally, LMND posted a remarkable 70.6% revenue growth to $844.7 M and generated positive free cash flow of $90.9 M, yet it remains unprofitable with a –11% operating margin and a forward P/E of –150.7. The DCF‑derived fair value of $44.6 is well beneath the current market price, suggesting the stock is priced above intrinsic estimates. While cash balances (~$394 M) comfortably exceed debt (~$200 M), the high debt‑to‑equity ratio (≈38.7) and negative ROE highlight financial strain. Analyst consensus leans “hold” with a median target of $62, and the market sentiment index reads “Extreme Greed,” reflecting optimism despite the underlying risks.
Fundamentally, LMND posted a remarkable 70.6% revenue growth to $844.7 M and generated positive free cash flow of $90.9 M, yet it remains unprofitable with a –11% operating margin and a forward P/E of –150.7. The DCF‑derived fair value of $44.6 is well beneath the current market price, suggesting the stock is priced above intrinsic estimates. While cash balances (~$394 M) comfortably exceed debt (~$200 M), the high debt‑to‑equity ratio (≈38.7) and negative ROE highlight financial strain. Analyst consensus leans “hold” with a median target of $62, and the market sentiment index reads “Extreme Greed,” reflecting optimism despite the underlying risks.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price trading below short‑term SMA levels
- Decreasing volume and elevated 30‑day volatility
- Recent earnings miss and negative profit margins
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Sustained ~70% revenue growth and accelerating in‑force premiums
- Positive free cash flow despite operating losses
- Potential upside toward analyst median target around $62
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Current price exceeds DCF fair value, indicating overvaluation
- Persistent operating losses and high beta increase downside risk
- Long‑term franchise potential with AI‑driven insurance model
Key Metrics & Analysis
Financial Health
Revenue Growth70.60%
Profit Margin-16.44%
P/E Ratio-150.7
ROE-26.12%
ROA-3.51%
Debt/Equity38.69
P/B Ratio8.0
Op. Cash Flow$30.1M
Free Cash Flow$90.9M
Industry P/E16.8
Technical Analysis
TrendBearish
RSI48.0
Support$50.80
Resistance$68.05
MA 20$56.14
MA 50$60.29
MA 200$63.89
MACDBullish
VolumeDecreasing
Fear & Greed Index91.71
Valuation
Fair Value$44.60
Target Price$59.56
Upside/Downside5.37%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta2.79
Volatility74.67%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.